News :: Fresh Tracks Therapeutics, Inc. (FRTX)

Contact Us

Feb 20, 2020 6:30am EST

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

Feb 18, 2020 6:30am EST

Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements

Jan 10, 2020 4:05pm EST

Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

Nov 13, 2019 4:05pm EST

Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Oct 30, 2019 4:42pm EDT

Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

Sep 03, 2019 6:00am EDT

Brickell Biotech Completes Merger with Vical

Jun 03, 2019 3:00am EDT

Vical and Brickell Announce Merger Agreement

Nov 19, 2018 9:00am EST

Brickell Biotech Appoints Top Lilly Executive, Robert Brown, as Chief Executive Officer

Feb 20, 2018 8:00am EST

Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Oct 24, 2017 8:00am EDT

Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis